Inactivation of Plasminogen Activator Inhibitor-1 Accelerates Thrombolysis of a Platelet-rich Thrombus in Rat Mesenteric Arterioles

Summary

To investigate the role of active plasminogen activator inhibitor 1 (PAI-1) in the evolution of a microthrombus generated in the arteriolar microcirculation, the monoclonal antibody, 33H1F7, which transforms active PAI-1 to a tissue type plasminogen activator (t-PA) substrate, was evaluated in an arteriolar thrombosis model in the rat mesentery. Arterioles (200-300 μm) were stimulated electrically to create an endothelial lesion; ADP was then perfused for 2 min to induce the formation of a platelet-rich thrombus which lysed spontaneously in 140 ± 24 s. Two successive ADP superfusions produced comparable thrombi which lysed in comparable times. Different doses of 33H1F7 were infused to rats for 30 min and the dose which inactivates rapidly and totally active rat PAI-1 (300 μg/kg/min) was selected to be tested on the thrombosis model. Infusion of 33H1F7 beginning 10 min before the ADP application significantly reduced the lysis time in comparison to the control (123 ± 30 s versus 169 ± 33 s, P < 0.05, paired Student’s t-test) and the cumulative thrombus area during the lysis period was decreased by 56 ± 7%. These results demonstrate that inactivation of PAI-1 is able to accelerate lysis of a platelet-rich clot in a mesenteric arteriole of the rat. Thus active PAI-1 most likely participates to the resistance to thrombolysis in the arteriolar microcirculation and its inactivation may shorten ischemic periods after microvascular obstruction such as e.g. during cerebral stroke.

Keywords

PAI-1 - thrombolysis - experimental model - microcirculation - rat

• References

• 1 Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-13.
• 2 Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992; 95: 115-7.
• 3 Wiman B. Plasmiogen activator inhibitor 1 in thrombotic disease. Curr Op Hematol 1996; 3: 372-8.
• 4 Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor 1 gene. Nature 1990; 346: 74-6.
• 5 Levi M, Biemond BJ, Van Zonnevield AJ, Ten Cate AW, Pannekoek H. Inhibition of plasminogen activator-1 results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-12.
• 6 Biemond BJ, Levi M, Coronel R, Janse MJ, Ten Cate AW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen-activator inhibitor type 1-neutralizing antibody. Circulation 1995; 91: 1175-81.
• 7 Van Giezen JJJ, Walhund G, Nerme V, Abrahamsson T. The Fab-fragmant of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thromb Haemost 1997; 77: 965-9.
• 8 Berry CN, Lunven C, Lechaire I, Girardot C, O’Connor SE. Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator type 1 in rat models of venous and arterial thrombosis. Br J Pharmacol 1998; 125: 29-34.
• 9 Bourgain RH, Vermarien H, Andries R, Vereeche F, Jacqueloot J, Rennies J, Blockeel E, Six F. Standardized in vivo model for the study of experimental arterial thrombosis: description of a method. Adv Exp Med Biol 1984; 180: 635-49.
• 10 Verbeuren TJ, Vallez MO, Lavielle Bouskela E. Activation of thromboxane receptors and the induction of vasomotion in the hamster cheek pouch microcirculation. Br J Pharmacol 1997; 122: 859-66.
• 11 Ngo TH, Verheyen S, Knockaert I, Declerck PJ. Monoclonal antibody-based immunoassays for the specific quantitation of rat PAI-1 antigen and activity in biological samples. Thromb Haemost 1998; 79: 808-12.
• 12 Debrock S, Declerck PJ. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta 1997; 1337: 257-66.
• 13 Padro T, Quax PHA, van der Hoogen CM, Roholl P, Verheijen JH, Emeis JJ. Tissue-type plasminogen activator and its inhibitor in rat aorta: effect of endotoxin. Arterioscler Thromb 1994; 14: 1459-65.